Trial | NCT01410955  Report issue

Title

Prevention of Irinotecan Induced Diarrhea by Probiotics
Prevention of Irinotecan Induced Diarrhea by Probiotics. A Phase III Study

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    46
Irinotecan is one of key drug used in the treatment of colorectal cancer. The incidence of irinotecan induced diarrhea varies between 60-90%, with severe diarrhea in 20-40%. The main cause of diarrhea is one of irinotecan metabolites, SN-38 which is in the liver glucuronidated and subsequently expelled into the intestine. Due to the bacterial enzyme beta-D-glucuronidase in intestinal lumen it is deconjugated. This form causes direct damage of intestinal mucosa associated with malabsorption and the development of diarrhea. It is known that probiotic bacteria, reduce activity of intestinal beta-D-glucuronidase and therefore these bacteria could be applied in the prevention of diarrhea in patients treated by this food supplement. Given their low toxicity, good tolerability, probiotics may be an important part of supportive therapy. This is a first study aimed to determine the effectiveness of the probiotics in the prophylaxis of irinotecan induced diarrhea due to reduction intestinal beta-D-glucuronidase activity.
Study Started
Dec 31
2011
Primary Completion
Dec 31
2013
Study Completion
Jan 31
2014
Last Update
Jan 23
2014
Estimate

Dietary Supplement Probiotic formula

Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.

Dietary Supplement Placebo

Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.

Probiotics Experimental

Patients receiving probiotics.

Placebo Placebo Comparator

Patients receiving placebo

Criteria 

Inclusion Criteria:

signed written informed consent
histologically proven colorectal cancer patients started new line of chemotherapy based on irinotecan
ECOG PS 0 - 1 at study entry
life expectancy more than 3 months
absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;

Exclusion Criteria:

impossibility to take oral medication
active infection treated by antibiotic therapy
ileostomy
hypersensitivity to study drug
any concurrent malignancy other than non-melanoma skin cancer, no other cancer in past 5 years.
serious concomitant systemic disorders or diseases incompatible with the study (at the discretion of investigator )
No Results Posted